<DOC>
	<DOCNO>NCT00547534</DOCNO>
	<brief_summary>The purpose study evaluate non-Hodgkin 's lymphoma respond , return standard treatment , respond bortezomib , rituximab bendamustine , also see effect drug combination cancer .</brief_summary>
	<brief_title>Pilot Study Bortezomib , Bendamustine Rituximab Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Voluntary write informed consent performance studyspecific procedure part routine medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control duration study . Male subject agrees use acceptable method contraception duration study . Histologicallyconfirmed indolent mantle cell lymphoma , utilizing World Health Organization ( WHO ) classification . The biopsy must fulfill one follow criterion : Follicular lymphoma , grade 13 Marginal zone lymphoma Small lymphocytic lymphoma ( circulate lymphocyte count must &lt; 5,000 ) Lymphoplasmacytic lymphoma Mantle cell lymphoma [ confirm cyclin D1+ FISH ( 11 ; 14 ) ] Age ≥ 18 year Must receive least one prior chemotherapy regimen lymphoma . Patients treat antibody therapy radiation therapy eligible . Zubrod performance status ≤ 3 Patients must measurable disease indication receive additional therapy Patient platelet count ≤75,000/mm^3 within 14 day enrollment . Patient absolute neutrophil count &lt; 1,000/mm^3 within 14 day enrollment . Patient calculate measured creatinine clearance &lt; 30 mL/minute within 14 day enrollment . Patient ≥ Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity boron mannitol Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum ßhuman chorionic gonadotropin ( ßhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive chemotherapy antibody therapy within 28 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Patient receive investigational drug 14 day enrollment Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Prior exposure bendamustine Prior exposure bortezomib Time Progression ( TTP ) bortezomib contain regimen &lt; 6 month . If TTP bortezomib contain regimen &gt; 6 month , patient allow enroll study . Patient concomitant active malignancy require therapy Patient know HIV positive ( test result require enrollment ) . History solid organ transplantation , post transplant lymphoproliferative disorder Patient history allogeneic stem cell transplantation . Patient history autologous stem cell transplantation radioimmunotherapy within previous 4 month . Patient receive investigational drug within 14 day prior enrollment History , clinically apparent CNS lymphoma Any clinically significant abnormality screen blood chemistry , hematology , urinalysis result , judgment investigator , would impede adequate evaluation adverse event and/or response treatment , require aggressive intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>Indolent</keyword>
</DOC>